WillItSurvive
Medical technology and health companies · United States

Dexcom

dexcom.com ↗

Dexcom makes wearable continuous glucose monitors that track blood sugar in real time for diabetics.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from July 30, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report showing whether US organic growth holds above high-single-digits
The call

Dexcom is growing and profitable, but Abbott's larger share and new sensor push, plus AI coaching apps riding its own data, squeeze the room to gain ground.

Dexcom manufactures continuous glucose monitors (small sensors that track blood sugar) used mostly by people with diabetes. The company is profitable and growing, but Abbott's FreeStyle Libre sensor is winning customers in Dexcom's most important market segment (people who take insulin), and Abbott is also building sensors that measure multiple things at once. Meanwhile, AI apps that give nutrition and meal advice are starting to do some of the coaching work Dexcom's software used to handle, which means patients might not need Dexcom's full service as much. The key thing to watch is whether Dexcom can hold its market share when Abbott keeps gaining ground, especially among insulin-dependent patients.

Why
01
AI pressure: SNAQ and similar AI nutrition/coaching apps built on Dexcom's data feed. AI meal-logging apps like SNAQ sit on top of Dexcom's sensor data, pulling coaching value away from Dexcom's own software layer. Could AI do the core job? Unlikely.
02
Bigger players: Abbott Laboratories (FreeStyle Libre). Abbott's Libre already holds roughly 53% of CGM share versus Dexcom's 34% and is pushing a dual-analyte sensor plus a Medtronic OEM deal into Dexcom's core Type-1 base. Could a giant copy it? Probably.
03
What protects it. FDA clearances, insurance reimbursement contracts, and pump-integration deals with Tandem, Omnipod, and iLet keep patients and prescribers locked into Dexcom sensors.
What would change this call
Dexcom's Q2 2026 earnings (July 30, 2026) show U.S. organic growth vs prior quarters. Slowing U.S. growth would show Abbott is converting Dexcom's core insulin-intensive users.
Uptake data on Abbott's dual-analyte (glucose+ketone) sensor after launch. Fast adoption would show Abbott capturing Type-1 patients Dexcom relies on.
Whether Omnipod, Tandem, or iLet pump integrations stay exclusive to Dexcom or add Abbott. A shift to Abbott would show Dexcom losing its distribution lock-in with pump partners.
Key numbers
  • FY2025 revenue $4.66B, up 15.6% YoY (2025-12-31)
  • Abbott Libre ~53% CGM share vs Dexcom ~34% (2026-Q1)
  • Stelo topped $100M revenue in first 12 months (2025-Q3)
Named risks
  • Abbott's ~53% CGM share and incoming dual-analyte sensor threaten Dexcom's core Type-1 segment. Severity: high
  • Feb 2024 FDA warning letter on San Diego plant signals ongoing manufacturing quality scrutiny. Severity: medium
  • Leadership transition instability after Sayer's medical leave and return as executive chairman, March 2026. Severity: medium
  • AI-native nutrition/coaching apps like SNAQ disintermediate Stelo's software differentiation. Severity: medium
  • Flagged 50-100bps gross margin headwind from fuel, resin and shipping costs heading into Q2 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Abbott Laboratorieslosing toAbbott holds ~52.8% CGM share vs Dexcom's 33.9% in 2025; Barclays downgrade Jan 12, 2026 cited widening gap
MedtroniccontestingAug 2024 Medtronic-Abbott 'Instinct' deal distributes Libre 3+ to Dexcom's installed base
SNAQ (AI nutrition app)contestingMay 2026 SNAQ pairs with Dexcom sensors, competing at Stelo's meal-logging/coaching software layer
Questions people ask
Is Dexcom profitable in 2026?
Yes. Dexcom posted FY2025 net income of $836.3 million on $4.66 billion revenue (Dec 31, 2025), and Q1 2026 net income hit $216.3 million, up 75% year over year, with operating margin expanding to 22.2% of revenue from 13.8% a year earlier.
Who is Dexcom's biggest competitor?
Abbott Laboratories' FreeStyle Libre is the dominant rival, holding roughly 52.8% of 2025 CGM shipment revenue versus Dexcom's 33.9%. Abbott's Libre franchise alone generated $2.08 billion in Q1 2026, more than Dexcom's entire quarterly revenue of $1.19 billion.
Could AI replace Dexcom's business?
No, the physical glucose sensor, FDA clearances, and Medicare/DME reimbursement network form a hardware moat AI cannot replicate. However, AI-native apps like SNAQ (compatible with Dexcom sensors, noted May 2026) compete directly with Stelo's meal-logging and coaching software layer.
Is Dexcom laying off employees?
No. Company-reported headcount grew to 11,100 employees as of December 31, 2025, up from 10,300 in 2024, a 7.8% increase, and up from 9,600 in 2023, showing continued hiring rather than cuts.
Who owns Dexcom?
Dexcom has no parent company; it has traded publicly on Nasdaq as DXCM since 2005 and joined the Nasdaq-100 in April 2020. Large institutional holders include State Street and Vanguard funds, with market capitalization near $28.8 billion as of July 22, 2026.
Is Dexcom losing market share to Abbott?
Yes. Barclays downgraded Dexcom to Underweight on January 12, 2026, citing Abbott's roughly 50% CGM share and its expansion into Dexcom's core Type-1 and insulin-intensive Type-2 segments via new dual-analyte sensor technology.
Timeline
  • 2026-07-13Dexcom G7 15 Day receives Health Canada authorization, not yet commercially launched
  • 2026-07-07Stelo app relaunched with AI coaching, pattern recognition, photo meal logging
  • 2026-06-30Dexcom G6 manufacturing ends, users transitioned to G7 or G7 15 Day
  • 2026-03-01Kevin Sayer returns as executive chairman after medical leave
  • 2026-01-12Barclays downgrades Dexcom to Underweight citing Abbott share threat
  • 2026-01-01Jake Leach becomes Dexcom CEO, succeeding Kevin Sayer
  • 2025-12-01Dexcom G7 15 Day launches in the United States
  • 2025-11-21FDA clears Smart Basal insulin-dose-optimizer feature for G7 15-Day
  • 2025-07-31Kevin Sayer announces plan to step down as CEO
  • 2024-02-01FDA warning letter cites manufacturing deficiencies at San Diego plant
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources